Short Interest in LifeVantage Co. (NASDAQ:LFVN) Drops By 5.4%

LifeVantage Co. (NASDAQ:LFVN) saw a large decrease in short interest in December. As of December 31st, there was short interest totalling 191,800 shares, a decrease of 5.4% from the December 15th total of 202,800 shares. Approximately 1.9% of the company’s stock are sold short. Based on an average daily trading volume, of 110,600 shares, the days-to-cover ratio is currently 1.7 days.

Analyst Ratings Changes

A number of equities research analysts have issued reports on LFVN shares. Lake Street Capital started coverage on shares of LifeVantage in a report on Thursday, December 19th. They set a “buy” rating and a $26.00 target price on the stock. Craig Hallum assumed coverage on shares of LifeVantage in a report on Tuesday, January 14th. They issued a “buy” rating and a $35.00 price objective on the stock.

Hedge Funds Weigh In On LifeVantage

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LFVN. Ritholtz Wealth Management grew its holdings in shares of LifeVantage by 65.2% during the fourth quarter. Ritholtz Wealth Management now owns 47,348 shares of the company’s stock worth $830,000 after buying an additional 18,682 shares in the last quarter. Barclays PLC grew its holdings in LifeVantage by 38.2% in the third quarter. Barclays PLC now owns 41,966 shares of the company’s stock valued at $507,000 after purchasing an additional 11,608 shares during the period. HighTower Advisors LLC purchased a new stake in LifeVantage in the third quarter valued at approximately $638,000. Capital Management Corp VA purchased a new stake in LifeVantage in the third quarter valued at approximately $5,073,000. Finally, Renaissance Technologies LLC grew its holdings in LifeVantage by 2.1% in the second quarter. Renaissance Technologies LLC now owns 855,118 shares of the company’s stock valued at $5,490,000 after purchasing an additional 17,300 shares during the period. Institutional investors and hedge funds own 35.32% of the company’s stock.

LifeVantage Trading Up 0.0 %

Shares of LFVN opened at $25.31 on Friday. LifeVantage has a twelve month low of $5.22 and a twelve month high of $27.38. The firm’s fifty day simple moving average is $16.74 and its 200-day simple moving average is $12.12. The firm has a market capitalization of $316.88 million, a price-to-earnings ratio of 79.10 and a beta of 0.82.

LifeVantage (NASDAQ:LFVN) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $0.15 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.15. LifeVantage had a net margin of 2.11% and a return on equity of 29.24%. The company had revenue of $47.21 million for the quarter.

LifeVantage Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were paid a $0.04 dividend. This represents a $0.16 annualized dividend and a dividend yield of 0.63%. The ex-dividend date was Monday, December 2nd. LifeVantage’s dividend payout ratio (DPR) is 50.00%.

About LifeVantage

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix.